Physician profile
Robert L Weeks
NPI 1487653168
$5,356.09
in general payments reported to CMS, 2019-2025
39 companies · $774 in 2025
The $774 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $719 · 2021: $700 · 2022: $754 · 2023: $837 · 2024: $780 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.25 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,005.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $803.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $425.53 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $368.27 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $362.44 | 2019-2020 | |
| Amgen INC. | $245.76 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $222.02 | 2019-2025 | |
| Dexcom, INC. | $207.11 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $161.65 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $158.23 | 2021-2024 | |
| Lilly USA, LLC | $151.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.80 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $131.39 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.30 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $110.40 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.